PHARMARON：(Re-publishedfordebtholdersinformation)ANNUALRESULTSANNOUNCEMENTFORTHEYEARENDEDDECEMBER312023.pdf

1、1Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in relia

2、nce upon the whole or any part of the contents of this announcement.Pharmaron Beijing Co.,Ltd.康龍化成(北京)新藥技術股份有限公司(a joint stock company incorporated in the Peoples Republic of China with limited liability)(Stock Code:3759)ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31,2023FINANCIAL SUMMARY

3、 AND HIGHLIGHTSYear ended December 31,20232022ChangeRMB000RMB000%Revenue11,537,99610,266,28812.4Gross profit4,094,8203,749,2769.2Profit attributable to owners of the parent1,601,0961,374,60416.5Non-IFRSs adjusted net profit attributable to owners of the parent1,903,4311,834,2713.8Net cash flows gene

4、rated from operating activities2,753,5392,142,81628.5 During the Reporting Period,the Group recorded aggregate revenue of approximately RMB11,538.0 million,representing an increase of approximately RMB1,271.7 million,or 12.4%,as compared to the year ended December 31,2022.During the Reporting Period

5、,the profit attributable to owners of the parent was approximately RMB1,601.1 million,representing an increase of approximately 16.5%as compared to the year ended December 31,2022.During the Reporting Period,the net cash flows generated from operating activities was approximately RMB2,753.5 million,

6、representing an increase of approximately 28.5%as compared to the year ended December 31,2022.The Board proposed to declare a final dividend of RMB2.0(inclusive of tax)per 10 shares or an aggregate of approximately RMB357.5 million for the year ended December 31,2023.The Board is pleased to announce